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Introduction
In the study of development and disease, the levels of receptor 
ligands and their downstream signaling pathways have received 
considerable attention, but less clear are the determinants of 
receptor availability at the cell surface. A sizeable proportion of 
receptors and transporters are located in endomembrane com-
partments that exchange with the cell surface pools (Wiley and 
Burke, 2001). Certainly, the number of receptors at the cell sur-
face is an important determinant of ligand-receptor complex for-
mation that affects signal strength (Dennis et al., 2009; Gurdon 
and Bourillot, 2001). Many cytokine receptors and transporters 
are cotranslationally modified with Asn (N)- and Ser/Thr (O)-linked 
oligosaccharides (glycans) and, together with proteoglycans and 
glycolipids, form the glycocalyx, an ?100 nM wide macromo-
lecular structure that dominates the cell surface. The remodeling 
of N-glycans in the Golgi is sensitive to metabolism, and, when 
combined with gene-encoded differences in N-glycan number 
per protein, glycoprotein concentrations at the cell surface can be 
differentially regulated according to their affinities for endogenous 
lectins (Lau et al., 2007). Herein, we posit that increasing meta-
bolic regulation of Golgi N-glycan biosynthesis in metazoan plays 
a role in adaptive cellular systems in postnatal life. Applying this 
model to disease states, we review data from mice and human 
studies linking genetic and metabolic dysregulation of protein 
N-glycosylation in congenital disorders and complex traits such 
as autoimmunity, cancer, and metabolic syndrome.
Glycans and Cell Surface Regulation
Cell surface transmembrane glycoproteins are localized to and 
exchanged between microdomains, including clathrin-coated 
pits, cholesterol-rich lipid rafts, adhesion junctions between 
cells, substratum focal adhesion, and, as discussed here, the 
galectin lattice. The galectins are N-acetyllactosamine-binding 
proteins, and their major ligands are Golgi-remodeled N-gly-
cans common to many glycoproteins at the cell surface (Patnaik 
et al., 2006). Galectins are redox-sensitive proteins produced 
in the cytosol and released by a nonclassical pathway where 
they first encounter glycoproteins in cargo vesicles (Delacour et 
al., 2007) and at the cell surface (Hughes, 1999). Galectins, as 
well as the siglec and selectin lectin families, are largely absent 
in unicellular eukaryotes (Drickamer and Fadden, 2002). The 
15 known galectins have either one or two carbohydrate rec-
ognition domains and mediate glycoprotein crosslinking (Lee 
and Lee, 2000). The extended C terminus of  galectin-3 forms 
multimeric structures (up to pentamers) driven by increasing 
concentrations of multivalent glycoprotein ligands, resulting in 
a molecular “lattice” or microdomain with irregular geometry 
at the cell surface (Ahmad et al., 2004; Demetriou et al., 2001). 
However, galectins with different lattice-forming geometries 
may bind glycoprotein partners selectively based on the N-gly-
can orientation (Brewer et al., 2002).
Cell surface transmembrane glycoproteins often bind cyto-
plasmic adaptor proteins that localize to coated-pits, lipid 
microdomains, or actin microfilaments. However, N-glycans 
on extracellular domains interact with lectins, which can 
restrict glycoprotein mobility, either enhancing or opposing 
intracellular tethers (Demetriou et al., 2001; Partridge et al., 
2004). For example, epidermal growth factor receptor (EGFR) 
is restrained from self-association and activation, but mod-
eling and experimental data implicates additional extrinsic 
mechanisms of restraint (Klein et al., 2004). One of these is 
galectin binding to the N-glycans on EGFR, which slows lat-
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eral diffusion and loss to coated-pit endocytosis in mammary 
carcinoma cells (Lajoie et al., 2007; Partridge et al., 2004). In 
human glioblastomas, an activating mutation in EGFR deletes 
part of the extracellular domain (EGFRvIII), removing four of 
12 N-glycan sites and increasing ligand-independent dimeriza-
tion (Fernandes et al., 2001). Domain II–IV normally confers 
intramolecular interactions that maintain the autoinhibited 
state, where the N-glycans in domain III contribute by block-
ing receptor dimerization and activation (Takahashi et al., 2008) 
(Tsuda et al., 2000). Therefore, in addi-
tion to opposing loss to endocytosis, 
N-glycans appear to “insulate” against 
ligand-independent EGFR dimerization. 
N-glycans extend from the protein sur-
face and may restrict the approaches 
between monomers for EGFR dimeriza-
tion. Galectin crosslinking is expected to 
separate glycoproteins by ?100 Å and 
appears to impose a physical barrier to 
spontaneous dimerization (Seetharaman 
et al., 1998) (Figure 1). However, the lat-
tice is not likely to be a barrier to growth 
factor-mediated receptor dimerization, 
as various cyokine affinities for cognate 
receptors are ?108–1012 M, whereas 
galectins affinities for glycans are lower, 
?10−5–10−7 M. Galectin-3 and -8 bind to 
β1 integrin and regulate focal adhesion 
turnover and cell motility (Lagana et al., 
2006; Levy et al., 2001). As expected for 
a multivalent system, addition of recombinant galectin to cells 
displays an optimum for stimulation of focal adhesion turnover. 
Galectin gene expression, export, and redox sensitivity are 
likely to be important aspects of lattice regulation and warrant 
further investigation.
The α and β subunits of the T cell receptor (TCR) are N-gly-
cosylated on at least seven Asn-X-Ser/Thr (NXS/T) sites, and 
the complex is assembled in the endoplasmic reticulum (ER) 
prior to N-glycan processing in the Golgi (Rudd et al., 1999). 
Figure 1. N-Glycan Branching Pathways 
and the Galectin Lattice
(A) N-glycan branching pathway. Oligosaccharyl-
transterase (OT) utilizes the preassembled donor 
Glc3Man9GlcNAc2-pp-dolichol to transfer the gly-
can to NXS/T motifs on glycoproteins in the endo-
plasmic reticulum (ER). Glycoproteins transit from 
the ER to cis, medial, and trans Golgi en route 
to the cell surface. The N-acetylglucosaminyl-
transferases enzymes, designated by their gene 
names (Mgat1, Mgat2, Mgat4, and Mgat5) gener-
ate branched N-glycans that display a range of 
affinities for galectins. The Km values for Mgat1, 
Mgat2, Mgat4, and Mgat5 are indicated as mea-
sured in vitro for UDP-GlcNAc and acceptor gly-
coproteins.
(B) Dynamics of the galectin lattice. The glyco-
calyx is the thick carbohydrate layer surrounding 
the cell. Glycan structures generated in the Golgi 
differ in affinities for galectins. Galectins crosslink 
glycoprotein receptors and oppose loss of epider-
mal growth factor receptors (EGFR) to Caveolin 
1-positive microdomains (1), coated-pit endocyto-
sis (2), precocious clustering of receptors (3), and 
F-actin-mediated entry of T cell receptor (TCR) 
into and exit of CD45 from ganglioside GM1-pos-
itive microdomains (blue) (4). Nutrient supply and 
growth signaling increase membrane remodeling, 
regulate metabolite flux through the hexosamine 
pathway to UDP-GlcNAc and N-glycan branching 
(Golgi) on receptors to promote surface retention 
by the galectin lattice (5).
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On naive T cells, galectin-3 binds to the T cell receptor (TCR) 
and opposes microfilament-dependent partitioning of TCR into 
lipid microdomains (ganglioside GM1 enriched) while blocking 
microfilament-dependent movement of the tyrosine phos-
phatase CD45 out of the lipid microdomain, thus removing 
a negative regulator of TCR-Lck signaling (Chen et al., 2007; 
Demetriou et al., 2001) (Figure 1). Importantly, galectin binding 
prevents spontaneous TCR oligomerization in the absence of 
antigen, thereby blocking recruitment of CD4-Lck to TCR and 
microfilament mediated transfer to lipid microdomains (Grigo-
rian et al., 2009). Galectin binding to TCR also impedes CD8 
binding, another example of insulating against complex forma-
tion that increases the threshold to TCR agonists (Demotte et 
al., 2008). The avidity of TCR for peptide-MHC is similar to that 
of galectin for poly-N-acetylalctosamine branched N-glycans 
(?10−5M), and, unlike EGFR, the galectin lattice competes for 
ligand induced TCR clustering and signaling. Mice deficient in 
the branching enzyme β1,6-N-acetylglucosaminyltransferaseV 
(Mgat5) or β1,3-N-acetylglucosaminyltransferase (β3GnT2), an 
enzyme that extends the β1,6 branches with poly-N-acetyl-
lactosamine, drops the barrier to TCR clustering and auto-
immune disease in vivo (Demetriou et al., 2001; Togayachi et 
al., 2007). Selective removal of specific NXS/T sites from TCR 
also enhances receptor diffusion, multimerization, and activa-
tion (Kuball et al., 2009). T cell activation results in adaptive 
changes in glycoprotein distribution at the surface down-
stream of increased nutrient uptake, membrane turnover, and 
N-glycan branching.
Similarly, oncogenesis stimulates membrane remodeling, 
N-glycan branching, and galectin-3 expression (Dennis et al., 
1987; Lanzetti et al., 2004; Takenaka et al., 2004). Therefore, 
tension appears to increase between membrane turnover and 
lattice-mediated protection of receptors from coated pits and 
loss to endocytosis (Figure 1). Cancer mutations that disrupt 
the endocytic machinery also protect growth receptors either 
at the cell surface or by maintaining their activity in endosomes 
(Mosesson et al., 2008). For example, Avalanche and rab5 
mutants in the Drosophila endocytic pathway inhibit internal-
ization of surface receptors to the early endosome; thus, an 
excess of surface growth receptors promotes growth signal-
ing (Bilder, 2004). However, the scrib-dlg-lgl tumor suppres-
sor pathway also disrupts trafficking and thereby signaling in 
endosomes by tumor necrosis factor (TNF)/JNK to mediate cell 
death (Igaki et al., 2009). Protein phosphatases are important 
constitutive suppressers of growth signaling in early endo-
somes and lipid microdomains (Reynolds et al., 2003). The 
ligands for receptor tyrosine phosphatases have been elusive, 
and regulation may involve galectins, as has been suggested 
for CD45 (Chen et al., 2007) (Figure 1).
In addition to coated-pit endocytosis and the galectin lattice, 
receptors exchange with other specialized membrane micro-
domains. For example, EGFR is tethered by epithelial cell junc-
tions, where it binds to the tumor suppressor neurofibroma-
tosis (NF2/Merlin), which reduces receptor sensitivity to EGF 
(Curto et al., 2007). Adhesion junctions are lost with cancer 
progression, in a process known as the epithelial to mesenchy-
mal transistion (EMT). EMT promotes actin remodeling, which 
stimulates increased trafficking of EGFR between endosomes 
and the cell surface. As a consequence, the ruffling edges of 
cells recruit and activate EGFR with lower ligand requirements 
(Moro et al., 2002).
Caveolin1 (Cav1) clusters in cholesterol-rich rafts and binds 
to conserved motifs found in EGFR and other signaling proteins, 
resulting in loss of responsiveness to growth factors (Okamoto 
et al., 1998). CAV1 maps to a tumor suppressor locus (D7S522; 
7q31.1) (Lee et al., 2002), but upregulation of N-glycan branch-
ing in mouse mammary tumor cells acts dominantly to protect 
EGFR from Cav1 suppression (Lajoie et al., 2007). The galectin 
lattice protects EGFR from loss to Cav1 microdomains (Lajoie 
et al., 2007). Cav-1 binds cholesterol in rafts and stabilizes the 
structure by reducing diffusion, and, interestingly, galectin-4 
and -9 binding to glycoproteins in lipid rafts has a stabilizing 
effect (Braccia et al., 2003; Tanikawa et al., 2008). As outlined 
below, both N-glycan number (sequence-encoded NXS/T) and 
Golgi N-glycan branching (context dependent) determine gly-
coprotein affinities for the lattice (Lau et al., 2007).
N-Glycoform Diversity
N-glycosylation of proteins begins with the cotranslational 
transfer of Glc3Man9GlcNAc2 to ?70% of lumenal N-X-S/T 
(where X ≠ Pro) motifs by oligosaccharyltransferase (Apweiler 
et al., 1999). N-glycosylation is enhanced by neighboring aro-
matic amino acids and turns that expose the motifs at the 
convex surface of the peptide, but is less efficient in the prox-
imity of disulfide bonds, the transmembrane domain, and at 
the termini of protein (Jones et al., 2005). After transfer and 
trimming of two glucose (Glc) units, the protein chaperones 
calnexin and calreticulin bind to Glc1Man9GlcNAc2, and the 
remaining Glc residue is recycled by α-glucosidase II and ER 
α-glucosyltransferase until folding is complete, allowing transit 
to the Golgi (Helenius and Aebi, 2004). However, most NXS/T 
sites are not required for protein folding, and site densities in 
most animal glycoproteins are higher than expected on the 
basis of sequence composition, consistent with a post-Golgi 
function at the cell surface.
Chaperone-assisted protein folding employs an ancient and 
relatively homogenous N-glycan structure required prior to 
the Golgi. In contrast, an explosion in structural diversity has 
occurred with metazoan evolution of the Golgi pathways. Man-
nose residues are removed in the cis Golgi, then the N-acetyl-
glucosaminyltransferases I, II, III, IV, and V (encoded by Mgat1, 
Mgat2, Mgat3, Mgat4a/b, and Mgat5) initiate the branches 
in a sequential pathway (Schachter, 1986) (Figure 1). Differ-
ing from the other Mgat enzymes, the N-acetylglucosamine 
(GlcNAc) added to the β-linked mannose residue by Mgat3 is 
not sequential, nor is it elongated with galactose, and it can 
block further branching by Mgat2, 4, and 5. In the trans Golgi, 
β1,4 galactosyltransferase catalyzes the addition of galactose 
to GlcNAc residues to generate N-acetyllactosamine units, 
the epitope for galectin binding. The β1,6GlcNAc-branched 
product of Mgat5 is the preferred acceptor for extension with 
additional N-acetyllactosamine units, which increases affin-
ity for galectins-1, -3,  -8, and  9 (Hirabayashi et al., 2002). For 
example, galectin-3 binds to mono-, bi-, tri-, tetra-antennary 
N-glycans, and tetra-antennary N-glycans with polyN-acetyl-
lactosamine with Kds of 4.0, 1.4, 0.78, 0.69, and >0.19 µM, 
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respectively, a synergistic increase with respect to N-acetyl-
lactosamine units (Galβ1,4GlcNAcβ1,3). Importantly, struc-
tural diversity is magnified by partial saturation of branching 
at each N-glycan, as well as variable termination with sialic 
acid (SA), fucose (Fuc), and/or N-acetylgalactosamine (Gal-
NAc). Terminal α2,6SA reduces N-glycan affinity for galectins, 
whereas GalNAc addition may increase affinities (Amano et 
al., 2003; Stowell et al., 2008).
In theory, the diversity of the polymerization of monosaccha-
rides into branched chains can increase in a factorial manner. 
However, the potential for N-glycan structural diversity in ani-
mal tissues is bounded by the specificities of Golgi enzymes 
encoded in animal genomes and their tissue-specific patterns of 
gene expression. Nonetheless, more than 40 structures (varia-
tions on branching and extension) have been identified on EGFR 
(Stroop et al., 2000). The protein environment of NXS/T sites can 
limit the accessibility to branching enzymes (Do et al., 1994), but 
even with some site-specific bias, considerable numbers of gly-
coforms are possible (Figure 2). For example, eight NXS/T sites 
in EGFR are occupied with N-glycans, and if we use a conserva-
tive estimate of 14 possible structures at each site, the potential 
number of glycoforms is 203,490, approximately ten times the 
number of surface EGFR molecules per cell (Lau et al., 2007). 
Glycoproteins differ in encoded NXS/T number, and this should 
influence the requirements of Golgi remodeling as a determinant 
of lattice avidity and surface retention.
NXS/T Multiplicity Encodes Lattice Affinity
The incidence of canonical N-glycosylation sequons (NXS/T, 
where X ≠ P) varies considerably between different glycopro-
teins. Receptor kinases that stimulate growth and proliferation, 
such as insulin receptor, EGFR, and platelet-derived growth 
factor receptor (PDGFR)] have approximately five times more 
NXS/T sites, longer extracellular domains, and more sites per 
100 amino acids than receptors that mediate organogenesis, 
differentiation, and arrest (such as Tie1, Musk, Ltk, ROR1/2, 
DDR1, TβR, and EphR) (Lau et al., 2007). These observations 
suggest that N-glycan numbers per peptide (multiplicity) is 
a conserved and functionally significant feature of receptor 
kinases. NXS/T sites are the primary determinant in N-glycan 
multiplicity, and, together with N-glycan branching, determine 
glycoform structures and affinity for the galectin lattice. Mem-
brane glycoproteins with only one or two N-glycans per pep-
tide are markedly dependent on branching for stable associa-
tion with the galectin lattice (Lau et al., 2007). Examples of low 
multiplicity glycoproteins shown to be dependent on branching 
are discussed below and include glucose transporter (GLUT4, 
GLUT2), cytotoxic T lymphocyte antigen–4 (CTLA-4), and 
TGF-β receptors (TβR).
Interaction of Metabolism with N-Glycan Number and 
Diversity
Fructose-6-P, glutamine, and acetyl-CoA are central to carbohy-
drate, nitrogen, and fatty acid metabolism and are also required 
for de novo uridine diphosphate-N-acetylglucosamine (UDP-
GlcNAc) biosynthesis by the hexosamine pathway (Grigorian et 
al., 2007). The Golgi UDP-GlcNAc antiporter exchanges uridine 
monophosphate (UMP) for UDP-GlcNAc and establishes the 
steady-state amounts of UDP-GlcNAc inside the Golgi. Although 
difficult to measure, estimates suggest that UDP-GlcNAc con-
centration is 15-fold higher in the Golgi (?1.5 mM) than in the 
cytoplasm (Waldman and Rudnick, 1990). UDP-GlcNAc levels 
are well above the Km for Mgat1 at 0.04 mM, but Mgat1 has a 
relatively low affinity for acceptor N-glycan at ?2 mM (Figure 
1). This relationship is reversed for Mgat4 and Mgat5 enzymes, 
where UDP-GlcNAc concentrations become limiting (Lau et al., 
2007; Sasai et al., 2002). In other words, Mgat1 and Mgat2 activi-
ties are suboptimal and limited by affinity for acceptors, whereas 
Mgat4 and Mgat5 activities are limited by UDP-GlcNAc concen-
tration. Thus, the degree of N-glycan branching is dependent on 
rates of bulk protein synthesis, notably 5′ cap-dependent mRNA 
translation stimulated by mTor/S6 kinase signaling, as well as 
the availability of key metabolites to UDP-GlcNAc biosynthesis. 
As a result, the high-affinity galectin ligands, the tri- and tetra-
antennary N-glycans, increase in an ultrasensitive manner as a 
function of UDP-GlcNAc availability (Lau et al., 2007). Ultrasen-
sitivity describes a stimulus/response relationship in which the 
response rises sharply over a narrow range of stimulus (a sig-
moid curve), with a Hill coefficient (nH) >1 indicating the devia-
tion from a graded (hyperbolic) response curve (Ferrell, 1996). 
These pathway dynamics result from decreasing Mgat1, 2, 4, 5 
activities moving down the pathway, decreasing affinities for the 
common substrate (Km for UDP-GlcNAc), sequential order, and 
limited reaction times due to transit of glycoprotein substrates 
through the Golgi (Lau et al., 2007).
Figure 2. Congenital Disorders of Glycosylation and Glycoforms
Glycoprotein isoforms or glycofoms differ based on N-glycan structures pres-
ent at each NXS/T site (not all sites are occupied). CDG type I alters glycoform 
distribution due to deficiencies in Glc3Man9GlcNAc2-pp-dolichol biosynthesis, 
leading to incomplete N-X-S/T site occupancy. CDG type II are deficiencies in 
Golgi remodeling or glycoprotein trafficking.
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In TCR and growth-promoting receptor tyrosine kinases 
(such as EGFR, insulin receptor, PDGFR) where N-glycan mul-
tiplicity is relatively high, a significant fraction of receptors are 
associated with the lattice, and only a slow graded increase 
occurs with rising UDP-GlcNAc (1.5 to 6 mM). In contrast, gly-
coproteins with one or two N-glycans (such as TβR, CTLA-4, 
and GLUT4) are largely below the threshold for stable associa-
tion with the galectin lattice, but increase in a switch-like (sig-
moidal) response to increasing UDP-GlcNAc concentration, 
mirroring the ultrasensitive output of tri- and tetra-antennary 
N-glycans by the branching pathway. Experimental data and 
computational modeling are consistent with this model for the 
retention of glycoproteins on the cell surface. Their half-lives 
are proportional to avidities for the lattice, and cell surface 
retention is countered by constitutive endocytosis (Lau et al., 
2007). To summarize, ultrasensitivity of the N-glycan branch-
ing pathway to UDP-GlcNAc allows differential regulation of 
surface glycoproteins on the basis of N-glycan number and 
metabolite flux. Thus, metabolic supply to the hexosamine 
pathway titrates glycoprotein expression at the cell surface 
with response dynamics characteristic of N-glycan number.
Consequences of N-Glycan Number
Receptor Kinases and Cancer
In nontransformed epithelial cells, surface EGFR, PDGF, and 
IGFR first increase in a shallow graded manner with increas-
ing UDP-GlcNAc, followed by TβR in a switch-like response. 
These dynamics of receptor regulation by hexosamine/Golgi/
lattice have features of an oscillating system that may sup-
port tissue homeostasis (Lau et al., 2007). The same stimulus 
(UDP-GlcNAc) promotes a Michaelis-Menten response and 
a sigmoidal response for high and low multiplicity receptors, 
respectively. The intervening delay allows growth signal-
ing and anabolic metabolism to prevail before the onset of 
negative regulation as UDP-GlcNAc rises to levels that retain 
the low multiplicity receptor. The TβR and receptor tyrosine 
kinase pathways often oppose each other in proliferation and 
differentiation. For example, self-renewal and pluripotency 
of cultured human embryonic stem cells is maintained by a 
precise ratio of fibroblast growth factor (bFGF) to Noggin, 
a bone morphogenic protein (BMP)/TGF-β antagonist (Xu 
et al., 2005). Similarly, BMP4 promotes the differentiation of 
tumor-initiating stem cells and inhibits growth of human glio-
blastoma cells in mice (Piccirillo et al., 2006). Canonical TβR/
SMAD2/3 signaling also slows cell-cycle progression by sup-
pressing c-myc expression (Matsuura et al., 2004; Seoane et 
al., 2004). c-Myc activity in tumors stimulates the uptake of 
glucose and glutamine, the major carbon sources for energy 
in cancer cells, and stimulates anabolic metabolism includ-
ing UDP-GlcNAc supply (DeBerardinis et al., 2008; Morrish et 
al., 2009). Low multiplicity of TβR and membrane remodeling 
in cancer cells reduces its surface levels. Although Raf/Mak/
Ets activation increases Mgat4 and Mgat5 gene expression 
(Buckhaults et al., 1997; Ishida et al., 2005; Takamatsu et al., 
1999), this appears to be insufficient to protect surface TβR, 
and conditions in cancer cells favor high-multiplicity growth 
receptors over TβR (Lau et al., 2007). Metabolic supplements 
to UDP-GlcNAc can restore TβR signaling and slow growth, 
suggesting that with a better understanding of N-glycosyla-
tion and metabolism, it may be possible to restore a “non-
transformed” distribution of surface glycoproteins (Lau and 
Dennis, 2008; Mendelsohn et al., 2007).
T Cell Activation
T cell activation and subsequent arrest/apoptosis are regulated 
by gene expression, but are also temporally affected by metabo-
lism and environmental cues (Alegre et al., 2001; Frauwirth et al., 
2002). Activation of naive T cells requires TCR clustering above 
a threshold number, which induces Erk/PI3K signaling, glucose 
uptake, and multiple rounds of cell division. The interval until 
growth arrest 4–5 days later is determined in part by stimulation 
of metabolite flux into UDP-GlcNAc supply (Lau et al., 2007). 
Branching is also driven to higher levels by increased transcript 
levels for mannosidases Ia, Ib, Ic, II, and IIx, as well as MGAT5 
(Chen et al., 2009). Similar to TβR, CTLA-4 has two NXS/T sites 
and displays an ultrasensitive response to UDP-GlcNAc to attain 
the branching required for surface retention and growth arrest 
(Lau et al., 2007). The levels of CTLA-4 transcript and intracellu-
lar protein increase markedly with TCR signaling during the early 
growth phase (Chikuma and Bluestone, 2002), but endosomal 
trafficking limits expression of CTLA-4 at the cell surface, keep-
ing it below the threshold for the induction of growth arrest until 
the avidity of CTLA-4 for the galectin lattice increases. Surface 
CTLA-4 promotes T cell motility, which dampens TCR-CD28 
signaling in blast cells leading to quiescent memory cell status 
or apoptosis (Schneider et al., 2006). T cells deficient in Mgat5 
are hypomorphic for CTLA-4 at the cell surface but not inside 
the cells, and surface levels can be rescued by supplementa-
tion to UDP-GlcNAc as well as via maximal CD28 costimula-
tion, which drives metabolism. Compensation for the absence 
of tetra-antennary glycans in Mgat5 deficient cells occurs by 
supplementation to early reactions leading to more triantennary 
N-glycans. Galectin-1-deficient mice are also susceptibility to 
autoimmune disease, and both galectins-1 and -3 play a role in T 
cell apoptosis (Stillman et al., 2006; Toscano et al., 2007).
Glucose Transporters
The glucose transporters GLUT2 and GLUT4, each with a single 
N-glycan, are dependent on branching and galectin binding for 
optimal surface retention (Lau et al., 2007; Ohtsubo et al., 2005). 
Insulin receptor (INSR) has 18 potential sites of N-glycan attach-
ment, a large disparity in multiplicity with GLUT2 and GLUT4 (n 
=1) conducive to differential regulation of metabolism by UDP-
GlcNAc supply to branching. INSR stimulates increased sur-
face residency of GLUT4 in muscle with a response described 
as “quantum” (ultrasensitive), and this effectively shuttles excess 
serum glucose into muscle (Coster et al., 2004). Supplementation 
to the hexosamine pathway also increases surface GLUT4 in a 
sharp sigmoidal response, and mutation of the GLUT4 NXS/T site 
blocks the response to UDP-GlcNAc. GLUT4 transgenic mice dis-
play increased UDP-GlcNAc levels in muscle, indicating positive 
feedback to the hexosamine pathway (Buse et al., 1996). Metabo-
lites can change very rapidly in cells regulated largely by allosteric 
mechanisms (Bailey, 1998), but the hexosamine/Golgi/lattice may 
adapt the cell surface to reflect conditions averaged over time. 
In this regard, diabetic hyperglycemia leads to TGF-β-dependent 
tissue fibrosis, possibly due to a chronic hexosamine-dependent 
increase in surface retention of TβR (Kolm-Litty et al., 1998).
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The Hexosamine Pathway
UDP-GlcNAc is required in the biosynthesis of most classes of 
extracellular glycopolymers, including the N- and O-glycans, 
glycolipids, chitin, hyluronic acid, and heparin sulfate proteo-
glycans. UDP-GlcNAc is essential in all three phylogenetic 
kingdoms, and the de novo synthesis pathway may have origi-
nated with passage of life through the “RNA world.” As a ves-
tige of this heritage, RNA transcripts for glutamine:fructose-6P 
aminotransferase (GFAT) in gram-negative bacteria have a 5′ 
aptomer that binds GlcNAc for allosteric control of its ribozyme 
activity. GlcNAc binding induces cleavage of the message 
and downregulates GFAT, which is a rate-limiting enzyme of 
the pathway (Winkler et al., 2004). GFAT catalyzes isomerase 
and amination reactions using glutamine as the amine donor, 
and the enzyme itself is allosterically inhibited by its product 
glucosamine-6-phosphate (GlcN-6P) and by UDP-GlcNAc in 
mammalian cells (Broschat et al., 2002). The substrates of the 
de novo pathway, fructose-6P, glutamine, and acetyl-CoA are 
highly regulated intermediates of carbon and nitrogen metabo-
lism (Figure 3).
In mammalian cells, N-acetylglucosamine (GlcNAc) and 
glucosamine (GlcN) are salvaged into the hexosamine path-
way from glycoconjugate turnover by hydrolysis of glycosidic 
linkages in lysosomes and transported 
into the cytoplasm by uncharacterized 
transporter(s), where they are phospho-
rylated and re-enter the UDP-GlcNAc 
pool. There are two routes for salvage of 
GlcN-6P: either acetylation to GlcNAc-
6P by glucosamine-6P N-acetyltrans-
ferase GNPAT1/Emeg32 (Boehmelt et 
al., 2000) and UDP-GlcNAc produc-
tion, or deamination and conversion to 
fructose-6P by glucosamine-6-phos-
phate isomerase/oscillin (GNPDA) and 
entry into glycolysis (Zhang et al., 2003) 
(Figure 3). Feedback inhibition of GFAT 
by GlcN-6P with possible activation of 
GNPDA directs most GlcN to fructose-
6P. In contrast, the product of GlcNAc-
6-kinase (NAGK) is transferred directly 
into UDP-GlcNAc as there appears to 
be little feedback inhibition beyond 
GNPAT1 (Grigorian et al., 2007). Thus, 
GlcNAc is spared from catabolism, is efficiently salvaged, 
and contributes to anabolic pathways of glycoprotein modifi-
cation in cultured mammalian cells.
UDP-GlcNAc is a precursor to cytidine monophosphate-
sialic acid (CMP-SA), the sugar-nucleotide donor utilized by 
siayltransferases to cap N- and O-glycans (Figure 3). Loss-of-
function mutations in the gene encoding UDP-GlcNAc 2-epi-
merase/ManNAc kinase (GNE/MNK) result in an autosomal 
recessive neuromuscular disorder in humans and early death 
in mice (Hinderlich et al., 1997). Supplementation of pregnant 
mice with ManNAc prolongs the survival of the Gne mutant 
pups (Galeano et al., 2007), further supporting a role for amino 
sugars as therapeutics.
O-GlcNAc transferase (OGT) adds O-GlcNAc to Ser/Thr res-
idues on many cytosolic proteins, and removal by O-GlcNA-
case results in their rapid turnover (Kreppel and Hart, 1999). 
OGT overexpression in liver or fat promotes insulin resistance 
and hyperleptinemia in mice (McClain et al., 2002). O-GlcNAc 
addition to hepatic FoxO1 promotes the expression of genes 
for gluconeogenesis (Housley et al., 2008). Similarly, OGT 
competes at AMPK phosphorylation sites in CRTC2, allowing 
nuclear translocation and transcription of gluconeogenesis 
genes (Dentin et al., 2008). Glucose starvation activates AMPK 
Figure 3. Biosynthesis of Sugar Nucleotides
De novo biosynthesis of UDP-GlcNAc is depen-
dent on glucose, glutamine, acetyl-CoA, and uri-
dine. UDP-GlcNAc is also the precursor for UDP-
GalNAc and CMP-SA biosynthesis. Gal, Man, and 
GlcN salvage/import (green) are facilitated by the 
hexose transporters (GLUTs), whereas GlcNAc 
and Fuc are taken up by bulk endocytosis. The 
sugar nucleotides are in red. Genes in blue are 
discussed in the text. Glc, glucose; Gal, galactose; 
Man, mannose; GlcN, glucosamine; Fuc, fucose; 
GalNAc, N-acetylgalactosamine; GlcNAc, N-
acetylglucosamine; NeuNAc, N-acetylneuraminic 
acid; Gln, glutamine.
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and upregulates OGT gene expression in cultured HepG2 
hepatocellular carcinoma cells, suggesting a role in metabolic 
homeostasis (Taylor et al., 2008). Recently, Drosophila super 
sex combs (Sxc/OGT) has been shown to be a member of the 
Polycomb group (PcG), and mutation of Sxc provide strong evi-
dence that O-GlcNAc is required for transcriptional repression 
of homeobox (HOX) proteins (Gambetta et al., 2009). N-glycan 
branching also regulates glucose homeostasis in whole animal 
studies (Cheung et al., 2007; Ohtsubo et al., 2005), and further 
work is required to determine how OGT, N-glycan branching, 
and the hexosamine pathway interact.
N-Glycan Branching in Evolution and Development
Phylogenetics provides insight into the role of an ultrasensitive 
N-glycan branching pathway. Most mature N-glycans in Ara-
bidopsis, C. elegans, and Drosophila are mannose-terminated 
structures, and, compared to mammals, very little branching 
occurs beyond mono- and a trace of biantennary (Zhu et al., 
2004). Curiously, β-N-acetylhexosaminidase activity in these 
species specifically removes most of the GlcNAc residues 
added by Mgat1, and this blocks further branching (Gutternigg 
et al., 2007). Considering enzyme affinities for UDP-GlcNAc, 
the levels of monoantennary N-glycans may depend largely on 
competition between Mgat1 and β-hexosaminidase, whereas 
the supply of UDP-GlcNAc may regulate the formation of 
bianntennary N-glycans by Mgat2 (Km ?1 mM for Mgat2 and 
<0.1 mM for Mgat1) (Figure 1). N-glycan branching in C. elegans 
and Drosophila may be more dependent on developmental 
regulation of Golgi enzymes and less on UDP-GlcNAc metabo-
lism (Figure 4). Furthermore, Golgi β-N-acetylhexosaminidase 
activity is not found in mammalian cells. This corresponds with 
the evolutionary expansion of the branching pathway in verte-
brates (which have more Mgat genes) generating higher-affinity 
galectin ligands. As described above, these features are key 
to differential regulation of glycoprotein with high verses low 
numbers of N-glycan attachment sites. Most receptor kinases 
in C. elegans and Drosophila have high NXS/T multiplicity, and, 
interestingly, vertebrates show an expansion of genes encod-
ing receptors with lower multiplicity (Lau et al., 2007). Nota-
bly, these are TGF-β/BMP, Eph receptors, and some classes 
of receptor tyrosine kinases. Evolutionary trends in N-glycan 
branching and NXS/T multiplicity may be due to selection 
pressures for conditional control of growth and the adaptive 
immune system in longer-lived animals.
Mouse embryos lacking all N-glycan branches because of 
Mgat1 deficiency die by E9.5, with defects in growth and mor-
phogenesis (Ioffe and Stanley, 1994; Metzler et al., 1994) (Figure 
4). Mgat2 initiates the second antenna and displays an absolute 
requirement for the prior action of Mgat1 and α-Mannosidase 
II, consistent with sequential evolution and regulation of the 
pathway described above. Human Mgat2 deficiency (CDG-
IIa) (Tan et al., 1996) and mice lacking Mgat2 (Wang et al., 
2001) display similar developmental and postnatal defects. 
Mice with mutations in genes encoding enzymes further down 
the branching pathway are viable, but they display postnatal 
defects in the immune system, metabolism, and tissue renewal 
and delays in cancer development. Mgat4a and Mgat5 both 
generate galectin ligands but have opposing effects on sys-
temic glucose homeostasis in gene knockout studies. Mgat4a 
is required for tri- and tetra-antennary N-glycans in pancreatic 
β cells, whereas Mgat5 generates tetra-antennary branches 
and is expressed more widely. Mgat5-deficient mice are resis-
tant to weight gain on an enriched diet, hypersensitive to fast-
ing, and mildly hypoglycemic (Cheung et al., 2007). In contrast, 
mice deficient in Mgat4a display hyperglycemia, obesity, and 
insulin insufficiency on an enriched diet (Ohtsubo et al., 2005). 
Mgat4a is required in the modification of the single N-glycan 
chain on GLUT2, which binds to galectins and promotes cell 
surface retention. Elevated GLUT2 increases glucose uptake in 
β cells, acting as a stimulus for insulin secretion at peak serum 
Figure 4. Mgat Deficiencies
Listed is the number of genes encoding Mgat ac-
tivities corresponding to the branching pattern 
shown above. C. elegans triple Mgat1 mutant 
worms develop normally but display altered sen-
sitivities to pathogenic bacteria (Shi et al., 2006). 
Mutation of Mgat1 in Drosophila leads to fused 
lobes in the brain, and to loss of motility in adult 
flies, possibly reflecting both developmental and 
metabolic deficiencies (Sarkar et al., 2006). A fused 
lobes (fdl) phenotype is also observed for loss of 
β-hexosaminidase, the enzyme that specifically 
removes GlcNAc added by Mgat1 (Léonard et al., 
2006). It is possible that a precise level of Mgat1 
product regulates a morphogen gradient that de-
fines the boundary between lobes. Mgat1-deficient 
embryos are growth impaired and display defects 
in neural tube closure (Ioffe and Stanley, 1994; Met-
zler et al., 1994). Mice lacking Mgat2 are small and 
display severe defects in multiple organs, which 
is comparable to human CDG-IIa. Reproduced by 
permission of Oxford University Press: Wang et al. 
(2001) Glycobiology 11 (12), 1051–1070. The prod-
uct of Mgat3 shown in brackets can be found in any 
of the structures shown, but its presence blocks 
further branching.
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glucose. Insulin responses appear to be normal in Mgat5-defi-
cient mice, but changes in GLUT4 surface retention in muscle 
and fat coupled with impaired glucagon responses in liver 
may contribute to the lean phenotype (Cheung et al., 2007). 
Surface expression of glucagon receptor and cAMP signaling 
are deficient in hepatocytes from Mgat5−/− mice, which may 
contribute to these phenotypes. Resistance to weight gain in 
Mgat5-deficient mice is rescued by supplementation of their 
drinking water with GlcNAc (A. Johswich, M. Ryczko, and 
J.W.D., unpublished data).
Muscle satellite cells and bone marrow cells from Mgat5-
deficient mice display an imbalance that favors Smad2/3 to Erk 
signaling, accompanied by an increased ratio of differentiation 
to renewal. In vivo, bone marrow osteoprogenitors and muscle 
satellite cells are depleted, and the normal aging processes 
in bone and muscle of Mgat5-deficient mice is accelerated 
(Cheung et al., 2007). Stem cell maintenance requires trophic 
factors and surface levels of cognate receptors, which both 
decline with normal aging (Conboy et al., 2005; Shiraha et al., 
2000). It is possible that intervention directed at hexosamine 
and other metabolic pathways might support the “youthful” 
distributions of surface glycoproteins that more effectively sup-
port stem cell renewal. Profiling or proteomics of the cell sur-
face by mass spectrometry has the potential to reveal critical 
changes in receptors and transporters (Wollscheid et al., 2009). 
The Klotho gene was identified as a senescence suppressor 
and encodes a putative α2,6 sialidase that enhances N-glycan 
affinity for galectin-1 and protects glycoproteins from coated-
pit endocytosis. Loss of Klotho results in increased retention 
of the surface renal Ca2+ and K+ channels TRPV5 and ROMK1, 
each with one available NXS/T site (Cha et al., 2009; Cha et 
al., 2008). Adaptation of the cell surface by metabolic flux to 
Golgi N-glycosylation in youth may buffer against environmen-
tal stresses and genetic variation, but declines with aging due 
to a shift from glycolytic to oxidative metabolism (Petersen et 
al., 2003). Thus, life history and genetic background may inter-
act through N-glycan-dependent regulation of glycoproteins 
to reveal late-onset diseases such as autoimmunity, metabolic 
disease, and cancer.
Congenital Disorders of Glycosylation
Congenital disorders of glycosylation (CDG) are hypomorphic 
defects in N-glycan biosynthesis and provide insight into the 
functions of N-glycans in humans. Type I CDGs are deficien-
cies in various enzymes in the biosynthetic pathway for Glc-
3Man9GlcNAc2-pp-dolichol, the donor for N-glycan addition. 
As a result, in CDG usage of NXS/T sites is reduced (reviewed 
in Jaeken and Matthijs, 2007) (Figure 2).
CDG-Ib is a deficiency in phosphomannose isomerase (PMI; 
Figure 3) that decreases the supply of guanosine diphosphate 
mannose (GDP-Man) for dolichol-pp-oligosaccharide synthe-
sis. Unlike most CDGs, the CDG-Ib defect can be treated with 
a monosaccharide supplement that alleviates the chronic post-
natal phenotypes (Freeze, 1998). Failure to thrive, coagulopa-
thies, protein-losing enteropathy, and liver fibrosis observed 
in CDG-Ib are improved by supplementation of the diet with 
mannose, which bypasses the defective step (conversion of 
Fru-6P to Man-6P) and increases Man-6P and GDP-Man by 
the action of hexokinase. Glucose deprivation in cultured cells 
causes reduced glycosylation of sites in EGFR and altered dis-
tribution at the plasma membrane (Konishi and Berk, 2003). 
Low-glucose conditions impair Glc3Man9GlcNAc2-pp-dol bio-
synthesis, giving rise to smaller intermediates and incomplete 
N-glycosylation. The resulting unfolded protein response acti-
vates PERK, which inhibits general translation by phosphory-
lating the translation initiation factor eIF2α, and this allows Glc-
3Man9GlcNAc2-pp-dol and N-glycosylation levels to recover 
(Shang et al., 2007). Fibroblast from patients with type I CDG 
displayed similar but moderate induction of PERK kinase, sug-
gesting that ER and metabolic stress may be a common fea-
ture of CDG-I (Lecca et al., 2005).
Subjects with defects in the Golgi and secretory pathway 
are classified as having type II CDG, which is characterized 
by reduced branching or extension to the N-glycans (Figure 
2). The clinical phenotypes of type I and II CDG are often simi-
lar. In addition to those clinical features noted above, features 
of type II CDG include psychomotor retardation, ataxia, sei-
zures, retinopathy, and dysmorphic features. These deficien-
cies arise from loss-of-function mutations in genes related 
to remodeling—notably, Mgat2 (CDG-IIa), α-glucosidase I 
(CDG-IIb), GDP-Fucose Golgi transporter (CDG-IIc), and β1,4-
galactosyltransferase (CDG-IId) (Jaeken and Matthijs, 2007). 
Leukocyte adhesion deficiency type II (LAD II or CDG-IId) 
is caused by a hypomorphic mutation in the Golgi GDP-Fuc 
transporter that reduces cell surface fucosylated glycans, 
and patients suffer recurrent infections due to a deficiency in 
selectin ligands. The fucose salvage pathway has the capac-
ity to generate very high concentrations of GDP-Fuc, sufficient 
to overcome a partial defect in Golgi GDP-fucose transport in 
patients (Marquardt et al., 1999) (Figure 3). Similarly, fucose 
fed to mice deficient in GDP-keto-4-keto-6-deoxymannose 
3,5-epimerase-4-reductase (FX) restores fucose content in 
glycoproteins (Smith et al., 2002). Although the developmental 
defects associated with CDG are irreversible, postnatal defects 
can in some cases be rescued by dietary supplements to sugar 
nucleotide pools. The similarities in CDG clinical phenotypes 
suggest that NXS/T site usage (CDG type I) and Golgi N-glycan 
remodeling (CDG type II) are largely convergent for glycopro-
tein localization at the cell surface and in matrix.
Glycosylation Defects in Complex Human Diseases
Metabolism is embedded with multiple feedback mechanisms, 
but homeostatic set points for glucose and fatty acid metabo-
lism change with aging in a manner that is poorly understood 
(Petersen et al., 2003). Autoimmune disease and sporadic 
cancers are examples of diseases with stochastic etiologies 
caused by one or a few cells expanding in a pathological man-
ner (Dennis et al., 2002). Therefore, small changes in homeo-
stasis can be clinically important in large cell populations, 
given sufficient time and external stresses.
CTLA-4 has low N-glycan multiplicity, is subject to high rates 
of constitutive endocytosis (Alegre et al., 2001), and requires 
the galectin lattice to promote T cell growth arrest (Lau et al., 
2007). A common polymorphism in CTLA-4 (T17A) reduces 
N-glycan occupancy at the two NXS/T sites by ?50% and 
diminishes surface expression (Anjos et al., 2002). Although 
CTLA-4-deficient mice display widespread autoimmunity 
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(Waterhouse et al., 1995), CTLA-4(Ala17) alone contributes lit-
tle risk to multiple sclerosis and rheumatoid arthritis in humans. 
However, the addition of fewer N-glycans can be viewed as a 
selective “CDG type I deficiency” with the potential to promote 
disease in combination with Golgi polymorphisms (“mild CDG 
type II deficiency”). Indeed, polymorphisms in human Mgat1 
alter branching and interact with CTLA-4(Ala17), and coinheri-
tance cooperatively suppresses CTLA-4 surface expression 
and synergistically increases the risk of multiple sclerosis and 
rheumatoid arthritis, with neither variant promoting disease in 
the absence of the other (H.-L. Chen, J.W.D., and M.D., unpub-
lished data). Importantly, both TCR sensitivity and defects in 
CTLA-4 surface expression are conditional on UDP-GlcNAc 
supply to the N-glycan branching pathway and are rescued by 
supplementation with GlcNAc. Dietary supplements of GlcNAc 
also suppress autoimmune diabetes in nonobese diabetic mice 
(Grigorian et al., 2007) and chronic inflammatory bowel disease 
in children (Salvatore et al., 2000).
Interestingly, several mouse strains, including PL/J, are prone 
to autoimmunity and are naturally hypomorphic for GlcNAc 
branching, with deficiencies in Mgat1, Mgat2, and Mgat5 
enzyme activities (Lee et al., 2007). PL/J mice are also meta-
bolic outliers among mouse strains, displaying features simi-
lar to Mgat5-deficient mice on a 129 or C57B6 background—
notably, small size, resistance to a high-fat diet, low respiratory 
quotient, and shorter life span. In addition to genetics, nutrient 
conditions during embryogenesis are known to affect skeletal 
development as well as metabolism later in life. A poor nutrient 
environment in utero appears to adapt the metabolic circuitry 
for harsh conditions in postnatal life (Gluckman and Hanson, 
2006). Poor human prenatal nutrition coupled with the high-
calorie diet readily available in industrialized nations may pre-
dispose to high body mass and diabetes (Bateson et al., 2004). 
Perhaps nutrient supply to the fetus or newborn influences the 
homeostatic set point for hexosamine/Golgi/lattice and quali-
tative aspects of extracellular matrix, acting as a metabolic and 
self-organizing regulatory network in post-natal life.
Emerging evidence also links N-glycan branching to specific 
functions in the nervous system. Mgat5 is also highly expressed 
in the central nervous system (Granovsky et al., 1995), and 
mice deficient in Mgat5 display resistance to depression-like 
behavior in response to stress (Soleimani et al., 2008). In most 
sporadic amyotrophic lateral sclerosis (ALS) patients, EAAT2 
protein and transport activity are reduced by 30%–90%, which 
is not readily explained by mRNA levels. However, an allele of 
EAAT2 with a point mutation that removes one of two N-glyco-
sylation sites suggests that surface expression is dependent 
on N-glycans, possibly because of retention by lectins (Aoki et 
al., 1998; Trotti et al., 2001). Oxygen radical stress is a promi-
nent feature of ALS that may also disrupt the lattice by oxida-
tion of galectins.
Concluding Remarks
Kuriyan and Eisenberg (2007) argue that an early driving force 
in natural selection was low-affinity colocalization of proteins 
that enhance mass action and subsequent evolution of many 
variations on high-affinity and allosteric control of protein net-
works. Structurally, the galectin lattice is a force for localization 
and organization of surface glycoproteins, but in an evolution-
ary sense, lectin-carbohydrate lattices may be tolerant to varia-
tion in structural details and still maintain essential parameters 
of the regulatory network. Lectins bind with low monomeric 
affinities, but multivalency allows a very wide range of affinities 
and provides flexibility for evolutionary insertion of new glycan 
structures. From a chemist’s view, the N-glycan pathway might 
appear to be a very imprecise process, essentially impos-
ing “entropy” to the interface of cells with their environment. 
However, in biological systems, variance is tolerated and often 
serves a feedback regulatory role at the network level (Cof-
fey et al., 1998; Maamar et al., 2007; Radman, 2001). Defining 
all glycoforms in time and space is obviously an unattainable 
goal, and is not likely to make a meaningful contribution to our 
understanding of cell behavior. Rather, glycoforms can be clas-
sified in terms of their affinity for the animal lectins and as part 
of a larger network that regulates membrane organization.
Finally, gene-gene and gene-environmental interactions 
underpin many complex trait diseases. As such, genome-wide 
screens in complex diseases such as type 2 diabetes, auto-
immunity, and cardiovascular disease generally find individual 
single-nucleotide polymorphisms that account for very modest 
risk (<1.5) and therefore only a small fraction of the total genetic 
risk for the disease in question (Manolio et al., 2009). Cell sur-
face glycoproteins regulate highly adaptive systems in animals, 
and their regulation in a conditional manner should permit heri-
table phenotypic variation, evolutionary fitness, and opportuni-
ties for radiation. However, greater adaptive potential may also 
come with greater risk of polygenic diseases and proliferative 
disorders such as cancer and autoimmune disease. We sug-
gest that genetic variations in hexosamine/N-glycan pathways 
and substrate glycoproteins interact with each other and with 
life-history changes in metabolism to account for a large por-
tion of “missing” risk for many chronic human diseases.
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